ClexBio Oversubscribes Financing Round Totalling USD 2.2M to Develop Engineered Human Blood Vessel Transplants

22 Jul, 2021

ClexBio Oversubscribes Financing Round Totalling USD 2.2M to Develop Engineered Human Blood Vessel Transplants
Photo by Adeolu Eletu on Unsplash

– ClexBio has secured US$2.2m in seed funding from private investors and governmental grants.
– The development of blood vessel transplants is facilitated by the company’s proprietary Competitive Ligand Exchange X-Linking (CLEX) technology that represents a breakthrough in the ability to manipulate delicate living cells at the microscale, a prerequisite for recreating functional biological tissue architectures in the lab.
– ClexBio’s research-heavy team brings many years of experience from top US and European universities and research institutes including Harvard University, Yale University, the Wake Forest Institute for Regenerative Medicine, EPFL, the technical University of Munich, NTNU, the University of Oslo, and SINTEF.

Biotechnology Western Europe
Crunchbase icon

Content report

The following text will be sent to our editors: